CoChat
Sign Up
Cited by 18

The DOI matches its Crossref record.

Functional significance of myocardial activity at 18F-FAPI PET/CT in hypertrophic cardiomyopathy identified by cardiac magnetic resonance feature-tracking strain analysis

Zhang, Yu, Dong, Zhixiang, Wang, Li, Wang, Yi-Lu, Chen, Bi-Xi, Su, Yao, Zhao, Shihua, Yang, Min-Fu·2023·European Journal of Nuclear Medicine and Molecular Imaging
DOI 10.1007/s00259-023-06411-0
Open this paper in CoChat — free account

Abstract

Purpose This study aimed to evaluate the functional significance of 18 F-labeled fibroblast activation protein inhibitor ( 18 F-FAPI) activity in hypertrophic cardiomyopathy (HCM) by comparison with cardiac magnetic resonance feature-tracking (CMR-FT) strain analysis. Methods A total of 49 HCM patients were included in this study. Two independent control groups of healthy participants with a matched age and sex to the HCM patients were also enrolled. Left ventricular (LV) 18 F-FAPI activity was analyzed for extent (FAPI%) and intensity (maximum target-to-background ratio, TBR max ). The CMR tissue characterization parameters of the LV included late gadolinium enhancement, native T1 value, and extracellular volume fraction. LV strain analysis was performed in radial, circumferential, and longitudinal peak strains (PS). Results Intense LV myocardial 18 F-FAPI uptake was observed in HCM patients, whereas no obvious uptake was detected in healthy participants (median TBR max , 9.1 vs. 1.2, p 18 F-FAPI activity and strain parameters. The number of positive 18 F-FAPI uptake segments (n = 653) was higher than that of hypertrophic segments (n = 190) and positive CMR tissue characterization segments (n = 525) (all p 18 F-FAPI uptake segments was lower than that of negative 18 F-FAPI uptake segments (median radial PS, 30.5 vs. 36.1, p = 0.026 and median circumferential PS, -18.4 vs. -19.7, p = 0.041). Conclusion 18 F-FAPI imaging can partially reflect the potential strain reduction in…

Overview

Integrity signals

Registry

Crossref · 10.1007/s00259-023-06411-0

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 45

  1. Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014;130:484–95. https://doi.org/10.1161/CIRCULATIONAHA.113.007094. · DOI · Paper page
  2. Bittencourt MI, Cader SA, Araújo DV, Salles ALF, Albuquerque FN, Spineti PPM, et al. Role of myocardial fibrosis in hypertrophic cardiomyopathy: a systematic review and updated meta-analysis of risk markers for sudden death. Arq Bras Cardiol. 2019;112:281–9. https://doi.org/10.5935/abc.20190045. · DOI
  3. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733–79. https://doi.org/10.1093/eurheartj/ehu284. · DOI · Paper page
  4. Maron BJ, Maron MS, Rowin EJ. Perspectives on the overall risks of living with hypertrophic cardiomyopathy. Circulation. 2017;135:2317–9. https://doi.org/10.1161/CIRCULATIONAHA.117.027738. · DOI · Paper page
  5. Mavrogeni S, Petrou E, Kolovou G, Theodorakis G, Iliodromitis E. Prediction of ventricular arrhythmias using cardiovascular magnetic resonance. Eur Heart J Cardiovasc Imaging. 2013;14:518–25. https://doi.org/10.1093/ehjci/jes302. · DOI
  6. Sara L. Myocardial fibrosis in hypertrophic cardiomyopathy: what remains to be proven? Arq Bras Cardiol. 2019;112:290–1. https://doi.org/10.5935/abc.20190043. · DOI
  7. Kurose H. Cardiac fibrosis and fibroblasts Cells. 2021;10:1716. https://doi.org/10.3390/cells10071716. · DOI
  8. McDowell KS, Arevalo HJ, Maleckar MM, Trayanova NA. Susceptibility to arrhythmia in the infarcted heart depends on myofibroblast density. Biophys J. 2011;101:1307–15. https://doi.org/10.1016/j.bpj.2011.08.009. · DOI
  9. Baum J, Duffy HS. Fibroblasts and myofibroblasts: what are we talking about? J Cardiovasc Pharmacol. 2011;57:376–9. https://doi.org/10.1097/FJC.0b013e3182116e39. · DOI
  10. Varasteh Z, Mohanta S, Robu S, Braeuer M, Li Y, Omidvari N, et al. Molecular imaging of fibroblast activity after myocardial Infarction using a 68Ga-labeled fibroblast activation protein inhibitor, FAPI-04. J Nucl Med. 2019;60:1743–9. https://doi.org/10.2967/jnumed.119.226993. · DOI
  11. Toms J, Kogler J, Maschauer S, Daniel C, Schmidkonz C, Kuwert T, et al. Targeting fibroblast activation protein: radiosynthesis and preclinical evaluation of an 18F-labeled FAP inhibitor. J Nucl Med. 2020;61:1806–13. https://doi.org/10.2967/jnumed.120.242958. · DOI
  12. Kessler L, Kupusovic J, Ferdinandus J, Hirmas N, Umutlu L, Zarrad F, et al. Visualization of fibroblast activation after myocardial infarction using 68Ga-FAPI PET. Clin Nucl Med. 2021;46:807–13. https://doi.org/10.1097/RLU.0000000000003745. · DOI
  13. Diekmann J, Koenig T, Zwadlo C, Derlin T, Neuser J, Thackeray JT, et al. Molecular imaging identifies fibroblast activation beyond the infarct region after acute myocardial infarction. J Am Coll Cardiol. 2021;77:1835–7. https://doi.org/10.1016/j.jacc.2021.02.019. · DOI
  14. Shi X, Lin X, Huo L, Li X. Cardiac fibroblast activation in dilated cardiomyopathy detected by positron emission tomography. J Nucl Cardiol. 2022;29:881–4. https://doi.org/10.1007/s12350-020-02315-w. · DOI
  15. Chen BX, Xing HQ, Gong JN, Guo XJ, Xi XY, Yang YH, et al. Imaging of cardiac fibroblast activation in patients with chronic thromboembolic pulmonary hypertension. Eur J Nucl Med Mol Imaging. 2022;49:1211–22. https://doi.org/10.1007/s00259-021-05577-9. · DOI
  16. Wang L, Wang Y, Wang J, Xiao M, Xi XY, Chen BX, et al. Myocardial activity at 18F-FAPI PET/CT and risk for sudden cardiac death in hypertrophic cardiomyopathy. Radiology. 2023;306:e221052. https://doi.org/10.1148/radiol.221052. · DOI · Paper page
  17. Xu J, Yang W, Zhao S, Lu M. State-of-the-art myocardial strain by CMR feature tracking: clinical applications and future perspectives. Eur Radiol. 2022;32:5424–35. https://doi.org/10.1007/s00330-022-08629-2. · DOI
  18. Xu HY, Chen J, Yang ZG, Li R, Shi K, Zhang Q, et al. Early marker of regional left ventricular deformation in patients with hypertrophic cardiomyopathy evaluated by MRI tissue tracking: The effects of myocardial hypertrophy and fibrosis. J Magn Reson Imaging. 2017;46:1368–76. https://doi.org/10.1002/jmri.25681. · DOI
  19. Vigneault DM, Yang E, Jensen PJ, Tee MW, Farhad H, Chu L, et al. Left ventricular strain is abnormal in preclinical and overt hypertrophic cardiomyopathy: Cardiac MR feature tracking. Radiology. 2019;290:640–8. https://doi.org/10.1148/radiol.2018180339. · DOI
  20. Song Y, Bi X, Chen L, Yang K, Chen X, Dong Z, et al. Reduced myocardial septal function assessed by cardiac magnetic resonance feature tracking in patients with hypertrophic obstructive cardiomyopathy: associated with histological myocardial fibrosis and ventricular arrhythmias. Eur Heart J Cardiovasc Imaging. 2022;23:1006–15. https://doi.org/10.1093/ehjci/jeac032. · DOI
  21. Zhang Y, Wang YL, Yang MF, Wang L. Cardiac fibroblast activation imaging in a patient with hypertrophic cardiomyopathy. J Nucl Cardiol. 2023;30:1697–9. https://doi.org/10.1007/s12350-022-02967-w. · DOI
  22. Wang S, Zhou X, Xu X, Ding J, Liu S, Hou X, et al. Clinical translational evaluation of Al18F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging. Eur J Nucl Med Mol Imaging. 2021;48:4259–71. https://doi.org/10.1007/s00259-021-05470-5. · DOI
  23. Ugander M, Oki AJ, Hsu LY, Kellman P, Greiser A, Aletras AH, et al. Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. Eur Heart J. 2012;33:1268–78. https://doi.org/10.1093/eurheartj/ehr481. · DOI
  24. Kawel-Boehm N, Maceira A, Valsangiacomo-Buechel ER, Vogel-Claussen J, Turkbey EB, Williams R, et al. Normal values for cardiovascular magnetic resonance in adults and children. J Cardiovasc Magn Reson. 2015;17:29. https://doi.org/10.1186/s12968-015-0111-7. · DOI
  25. Liu J, Zhao S, Yu S, Wu G, Wang D, Liu L, et al. Patterns of replacement fibrosis in hypertrophic cardiomyopathy. Radiology. 2022;302:298–306. https://doi.org/10.1148/radiol.2021210914. · DOI
  26. Petersen SE, Jerosch-Herold M, Hudsmith LE, Robson MD, Francis JM, Doll HA, et al. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Circulation. 2007;115:2418–25. https://doi.org/10.1161/CIRCULATIONAHA. · DOI
  27. Chaldoupi SM, Loh P, Hauer RN, de Bakker JM, van Rijen HV. The role of connexin40 in atrial fibrillation. Cardiovasc Res. 2009;84:15–23. https://doi.org/10.1093/cvr/cvp203. · DOI
  28. Treutlein C, Distler JHW, Tascilar K, Fakhouri SC, Györfi AH, Atzinger A, et al. Assessment of myocardial fibrosis in patients with systemic sclerosis using [68Ga] Ga-FAPI-04-PET-CT. Eur J Nucl Med Mol Imaging. 2023;50:1629–35. https://doi.org/10.1007/s00259-022-06081-4. · DOI
  29. Siebermair J, Köhler MI, Kupusovic J, Nekolla SG, Kessler L, Ferdinandus J, et al. Cardiac fibroblast activation detected by Ga-68 FAPI PET imaging as a potential novel biomarker of cardiac injury/remodeling. J Nucl Cardiol. 2021;28:812–21. https://doi.org/10.1007/s12350-020-02307-w. · DOI
  30. Xie B, Wang J, Xi XY, Guo X, Chen BX, Li L, et al. Fibroblast activation protein imaging in reperfused ST-elevation myocardial infarction: comparison with cardiac magnetic resonance imaging. Eur J Nucl Med Mol Imaging. 2022;49:2786–97. https://doi.org/10.1007/s00259-021-05674-9. · DOI
  31. Barton AK, Tzolos E, Bing R, Singh T, Weber W, Schwaiger M, et al. Emerging molecular imaging targets and tools for myocardial fibrosis detection. Eur Heart J Cardiovasc Imaging. 2023;24:261–75. https://doi.org/10.1093/ehjci/jeac242. · DOI
  32. Moon JC, Reed E, Sheppard MN, Elkington AG, Ho SY, Burke M, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;43:2260–4. https://doi.org/10.1016/j.jacc.2004.03.035. · DOI
  33. Moravsky G, Ofek E, Rakowski H, Butany J, Williams L, Ralph-Edwards A, et al. Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR. JACC Cardiovasc Imaging. 2013;6:587–96. https://doi.org/10.1016/j.jcmg.2012.09.018. · DOI
  34. Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. 2012;5:370–7. https://doi.org/10.1016/j.jcmg.2011.11.021. · DOI
  35. Mentias A, Raeisi-Giglou P, Smedira NG, Feng K, Sato K, Wazni O, et al. Late gadolinium enhancement in patients with hypertrophic cardiomyopathy and preserved systolic function. J Am Coll Cardiol. 2018;72:857–70. https://doi.org/10.1016/j.jacc.2018.05.060. · DOI
  36. Ambale-Venkatesh B, Lima JA. Cardiac MRI: a central prognostic tool in myocardial fibrosis. Nat Rev Cardiol. 2015;12:18–29. https://doi.org/10.1038/nrcardio.2014.159. · DOI
  37. Popescu BA, Rosca M. Imaging of myocardial fibrosis in hypertrophic cardiomyopathy: what is the gold standard? Heart. 2014;100:605–6. https://doi.org/10.1136/heartjnl-2013-305359. · DOI
  38. Taylor AJ, Salerno M, Dharmakumar R, Jerosch-Herold M. T1 mapping: basic techniques and clinical applications. JACC Cardiovasc Imaging. 2016;9:67–81. https://doi.org/10.1016/j.jcmg.2015.11.005. · DOI
  39. Parekh K, Markl M, Deng J, de Freitas RA, Rigsby CK. T1 mapping in children and young adults with hypertrophic cardiomyopathy. Int J Cardiovasc Imaging. 2017;33:109–17. https://doi.org/10.1007/s10554-016-0979-9. · DOI
  40. Ho CY, Abbasi SA, Neilan TG, Shah RV, Chen Y, Heydari B, et al. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. Circ Cardiovasc Imaging. 2013;6:415–22. https://doi.org/10.1161/CIRCIMAGING.112.000333. · DOI
  41. Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation. 2010;122:138–44. https://doi.org/10.1161/CIRCULATIONAHA.109.930636. · DOI
  42. Li Y, Liu X, Yang F, Wang J, Xu Y, Fang T, et al. Prognostic value of myocardial extracellular volume fraction evaluation based on cardiac magnetic resonance T1 mapping with T1 long and short in hypertrophic cardiomyopathy. Eur Radiol. 2021;31:4557–67. https://doi.org/10.1007/s00330-020-07650-7. · DOI
  43. Hinojar R, Fernández-Golfín C, González-Gómez A, Rincón LM, Plaza-Martin M, Casas E, et al. Prognostic implications of global myocardial mechanics in hypertrophic cardiomyopathy by cardiovascular magnetic resonance feature tracking. Relations to left ventricular hypertrophy and fibrosis. Int J Cardiol. 2017;249:467–72. https://doi.org/10.1016/j.ijcard.2017.07.087. · DOI
  44. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599–726. https://doi.org/10.1093/eurheartj/ehab368. · DOI · Paper page
  45. Yang L, Zhang L, Cao S, Gao C, Xu H, Song T, et al. Advanced myocardial characterization in hypertrophic cardiomyopathy: feasibility of CMR-based feature tracking strain analysis in a case-control study. Eur Radiol. 2020;30:6118–28. https://doi.org/10.1007/s00330-020-06922-6. · DOI

Cited by

Sorted by citations

See all 18

Metadata

Authors
Zhang, Y., Dong, Z., Wang, L., Wang, Y.-L., Chen, B.-X., Su, Y., Zhao, S., & Yang, M.-F.
Venue
European Journal of Nuclear Medicine and Molecular Imaging
Publisher
Springer Science and Business Media LLC
Published
2023-08-29
Volume
51
Issue
1
Pages
110-122
ISSN
  • 1619-7070
  • 1619-7089
DOI
10.1007/s00259-023-06411-0
Cited by
18
References
0
Language
en
Licence
Funders
  • National Key Research and Development Program of China (2021YFF0501401, 2021YFF0501402, 2021YFF0501400)
  • Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support (ZYLX202105)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Functional significance of myocardial activity at 18F-FAPI PET/CT in hypertrophic cardiomyopathy identified by cardiac magnetic resonance feature-tracking strain analysis. https://app.cochat.ai/papers/10.1007/s00259-023-06411-0
The paper
Zhang, Y., Dong, Z., Wang, L., Wang, Y.-L., Chen, B.-X., Su, Y., Zhao, S., & Yang, M.-F. (2023). Functional significance of myocardial activity at 18F-FAPI PET/CT in hypertrophic cardiomyopathy identified by cardiac magnetic resonance feature-tracking strain analysis. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-023-06411-0